Abstract
Neuropsychiatric symptoms (NPS) are increasingly recognized as early non-cognitive manifestations in the Alzheimer’s disease (AD) continuum. This study investigated whether NPS serve as early markers of pathophysiological progression by examining cognitively intact individuals with Dominantly Inherited Alzheimer’s Disease (DIAD) mutations. Using longitudinal data, researchers found that higher NPS scores, particularly in an "agitation" subsyndrome, were associated with significant metabolic decline in brain regions vulnerable to AD well before the onset of cognitive impairment. These findings suggest that NPS represent early manifestations of neuronal injury in the AD process.
Introduction
While Alzheimer’s disease (AD) is traditionally defined by cognitive decline, behavioral and psychological symptoms—collectively known as neuropsychiatric symptoms (NPS)—are frequently present. Historically viewed as secondary reactions to memory loss or late-stage complications, emerging evidence suggests NPS may actually be early clinical manifestations of the underlying pathophysiology.
To investigate this, researchers turned to Dominantly Inherited Alzheimer’s Disease (DIAD). Because DIAD is caused by specific genetic mutations with nearly 100% penetrance, it allows for the study of young, cognitively "normal" individuals who are certain to develop the disease. This provides a "clean" model of AD progression, free from the confounding age-related pathologies (like vascular disease) typical of late-onset cases.
Methods and Study Population
The study analyzed longitudinal data from 221 cognitively intact participants (Clinical Dementia Rating of 0) from the Dominantly Inherited Alzheimer’s Network (DIAN). Participants were stratified into mutation carriers (destined to develop AD) and non-carriers (healthy controls).
As shown in Table 1, while both groups were cognitively similar—evidenced by high Mini-Mental State Examination (MMSE) scores (~29)—mutation carriers already exhibited significant differences in cerebrospinal fluid (CSF) biomarkers. Specifically, they showed lower CSF Aβ1-42 and significantly higher tau levels (p < 0.001), indicating that underlying AD pathology was present despite the absence of cognitive symptoms.
The researchers utilized [18F]flurodeoxyglucose ([18F]FDG) positron emission tomography (PET) scans to measure glucose metabolism as a proxy for neuronal health. Behavioral domains were quantified using the Neuropsychiatric Inventory-Questionnaire (NPI-Q). A critical temporal metric was Estimated Years of Onset (EYO), which calculates the number of years a participant is from their expected symptom onset based on family history.
Results: NPS as a Metabolic Warning Sign
The study revealed that NPS are not merely psychological side effects but biological indicators of neuronal injury in individuals destined for AD.
Global and Regional Decline
In mutation carriers, the interaction between higher NPI-Q scores and shorter EYO (being closer to expected onset) was significantly associated with global metabolic decline. Voxel-based analysis identified specific "hotspots" of decline in the posterior cingulate cortex (PCC), ventromedial prefrontal cortex (vmPFC), bilateral parietal lobes, and the right insula. These regions are core components of the Default Mode Network (DMN) and the Salience Network (SN), which are known to be highly vulnerable to AD pathology.
The Impact of Subsyndromes
An exploratory factor analysis identified a specific neuropsychiatric subsyndrome—comprising agitation, disinhibition, irritability, and depression—that most strongly drove the decline in glucose uptake. Crucially, the link between NPS and metabolic decline was absent in non-mutation carriers. This suggests that these behavioral changes are specifically tied to the AD pathological process rather than general aging or stress.
Discussion and Future Directions
These findings support a conceptual framework where NPS represent early manifestations of neuronal injury in AD. The study shifts the perspective of NPS from "psychological side effects" to "biological indicators" that herald metabolic decline.
However, the researchers noted limitations, such as the use of the NPI-Q, which was originally designed for patients who already have dementia and may lack the sensitivity to capture very subtle behavioral shifts in pre-symptomatic stages. Future research should utilize tools like the Mild Behavioral Impairment Checklist (MBI-C) to better characterize these early symptoms.
Ultimately, recognizing NPS as early markers of metabolic decline could improve early diagnosis and provide new targets for intervention in the pre-symptomatic phase of Alzheimer’s disease.
Summary updated